Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health & Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.

开始日期2026-09-01

申办/合作机构

Oregon Health & Science University

[+1]

NCT07575672

/ Not yet recruiting临床3期IIT

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.

开始日期2026-07-01

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT07192952

/ Not yet recruiting临床3期

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure with left ventricular systolic dysfunction (LVSD) is a condition where the left side of the heart is weak and struggles to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and poor growth.
The study treatment, finerenone (also called BAY94-8862), is under development to treat newborns, children, and young adults with heart failure and LVSD. It works by blocking a protein that contributes to inflammation, scarring, and thickening in the heart and blood vessels, which may help the heart pump more blood effectively.
The main purpose of this study is to learn about how safe finerenone is and how well it works in the long-term treatment of heart failure and LVSD.
To understand how safe the treatment is, the study team will gather information on the number of patients who experience medical problems after taking finerenone, also known as "treatment emergent adverse events" (TEAEs). Additionally, they will collect blood samples to measure levels of an electrolyte called potassium and monitor blood pressure. They will also assess kidneys function using the estimated glomerular filtration rate (eGFR).
In this study, which is an extension of the earlier done FIORE study, finerenone will also be studied in newly enrolled newborns under 6 months with heart failure and LVSD and children and young adults from the FIORE study. The participants will be aged from newborns up to 18 years. All the participants will continue to receive their standard treatment as routine care for heart failure, along with finerenone during the study.
The participants will be in the study for around 10 to 11 months, depending on whether they rolled-over from the FIORE study or are newly enrolled newborns and infants <6 months of age. They will take study treatment for up to 9 months. During this period, at least 6 visits are planned for participants. During these visits, the study team will:
* have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured
* have blood samples taken
* have physical examinations
* have their heart examined by an electrocardiogram and echocardiography
* answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answer
* for newborns and infants, evaluate the acceptability of the study drug formulation through parents or guardians' feedback.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
The doctors will check the participants' health a month after the participants take their last treatment.

开始日期2026-06-01

申办/合作机构

Bayer AG

100 项与非奈利酮相关的临床结果

登录后查看更多信息

100 项与非奈利酮相关的转化医学

登录后查看更多信息

100 项与非奈利酮相关的专利（医药）

登录后查看更多信息

833

项与非奈利酮相关的文献（医药）

2026-12-31·RENAL FAILURE

Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

Article

作者: Shen, Xiaogang ; Zhu, Bin ; Yu, Jing-ting ; Zhuo, Cheng-cong ; Lin, Bo ; Zhang, Wei ; Jiang, Zhi-liang ; Zhang, Yu-jia ; Chen, Maosheng ; Zhou, Yi-dong

OBJECTIVE:

To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).

METHODS:

This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025. The finerenone group received conventional therapy plus finerenone, while the controls received conventional therapy alone. Outcomes included 24-h urinary protein (UP24), estimated glomerular filtration rate (eGFR), and adverse events (AEs). Propensity score matching (PSM) was used to balance baseline characteristics (28 patients/group).

RESULTS:

After 1:1 PSM, the finerenone group demonstrated a sustained reduction in UP24, from 742 ± 519 mg at baseline to 380 ± 333 mg (p < 0.001), while the control group showed no significant improvement at 12 months (p = 0.402). A similar trend of proteinuria reduction was observed at 3 and 6 months in the finerenone group. The between-group difference in ΔUP24 was significant at 12 months (finerenone: -393 ± 506 mg vs. control: +235 ± 1114 mg, p = 0.027). Finerenone demonstrated better preservation of eGFR at 12 months compared to controls after matching (ΔeGFR: +3.43 ± 8.25 vs. -5.99 ± 7.31 mL/min/1.73 m², p < 0.001). Safety profiles, including the incidence of hyperkalemia, elevated ALT, hypotension, and overall AEs, were comparable between the groups.

CONCLUSIONS:

Finerenone significantly reduced proteinuria and preserved eGFR in patients with IgAN over 12 months, with a favorable safety profile, suggesting potential benefit as an adjunctive treatment, pending randomized controlled trial confirmation. This study provides real-world, hypothesis-generating evidence for finerenone in IgAN, which can inform future RCT design and meta-analyses.

2026-07-01·BIOCHEMICAL PHARMACOLOGY

Finerenone improves doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte apoptosis through the TAK1-p38 axis

Article

作者: Lai, Xingyi ; Wu, Shaojun ; Zhang, Jiaming ; Xie, Huihui ; Wang, Lian ; Wang, Yu

Although doxorubicin (DOX) is a potent chemotherapeutic agent, its clinical use is limited by dose-dependent cardiotoxicity. Doxorubicin-induced cardiotoxicity (DIC) promotes cardiomyocyte apoptosis, which leads to cardiac dysfunction, remodeling, and even heart failure. Although Finerenone (Fin), a selective mineralocorticoid receptor antagonist, has demonstrated benefit in the treatment of heart failure, its role in DIC remains unclear. Our study found that Finerenone mitigated myocardial injury, cardiac dysfunction, fibrosis, and remodeling by attenuating DOX-induced cardiomyocyte apoptosis, and it improved survival in a DIC mouse model. Similarly, Finerenone reduced injury and apoptosis in DOX-treated H9c2 cells. We identified key targets of Finerenone in DIC using proteomics and network pharmacology and demonstrated that it prevented the upregulation of p38 phosphorylation induced by DOX. Through in vitro experiments, we confirmed that TAK1-p38 played a critical role in mediating the protective effects of Finerenone against DIC. Furthermore, we found that Finerenone inhibits TAK1-p38 phosphorylation and cardiomyocyte apoptosis by antagonizing MR to suppress ROS. Overall, these results suggested that Finerenone ameliorated DIC primarily by inhibiting cardiomyocyte apoptosis via the TAK1-p38 pathway. Our findings elucidate a key mechanism underlying the cardioprotective effect of Finerenone in DIC and provide a theoretical basis for expanding its clinical applications.

2026-07-01·CURRENT PROBLEMS IN CARDIOLOGY

Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease

Review

作者: Filippatos, Charalampos ; Duque, Ernesto Ruiz ; Xanthopoulos, Andrew ; Tepetes, Nikolaos-Iason ; Kourek, Christos ; Boutsikos, Ioannis ; Kostakou, Peggy ; Briasoulis, Alexandros ; Filippatos, Theodosios

PURPOSE:

Mineralocorticoid receptor antagonists (MRAs) are pivotal in managing cardiorenal disease, yet head-to-head comparisons across distinct phenotypes remain limited. This real-world study aims to compare their effectiveness and safety profiles in the context of cardio-renal-metabolic disease.

METHODS:

Using the TriNetX global health research network, adult patients initiating spironolactone, eplerenone, or finerenone (concurrent with SGLT2 inhibitors) were identified. Stratification included five cohorts: HFrEF, HFpEF, CKD, DM and non-DM. Pairwise 1:1 propensity score matching was performed.

RESULTS:

In patients with heart failure, finerenone was associated with a significant reduction in HF events compared to steroidal MRAs (HFrEF: HR 0.75; HFpEF: HR 0.62; p < 0.001 for both), though no significant differences were observed in overall survival or in other cardiovascular outcomes. However, it also seemed to be associated with trend of increased risk of hyperkalemia (HFrEF: HR 1.42, p = 0.103; HFpEF: HR 1.41, p = 0.057), compared to steroidal MRAs. On the other hand, in the CKD, DM, and non-DM cohorts, finerenone exhibited comprehensive superiority, significantly reducing the risk of death and the risk of cardiovascular events, compared to steroidal MRAs. Regarding safety, the non-steroidal MRA was associated with a lower risk of acute kidney injury (AKI) across CKD, DM, and non-DM phenotypes and a significantly reduced risk of hyperkalemia in CKD and non-DM patients.

CONCLUSION:

Finerenone appears superior for cardiorenal protection in CKD and metabolic phenotypes, whereas steroidal MRAs offer a favorable efficacy-safety balance in HF. These observations are hypothesis-generating and support phenotype-specific, individualized selection of MRAs pending validation in further prospective research.

854

项与非奈利酮相关的新闻（医药）

2026-05-26

·丁香园 Insight 数据库

拜耳潜在重磅炸弹新适应症申报上市，并获优先审评

5 月 21 日，拜耳宣布，美国 FDA 已受理非奈利酮的新适应症上市申请，并授予其优先审评资格，用于治疗 1 型糖尿病相关慢性肾脏病（CKD）。截图来源：拜耳官网非奈利酮（Finerenone）是一种选择性非甾体类盐皮质激素受体拮抗剂（nsMRA），目前已在全球 100 多个国家和地区获批用于治疗 2 型糖尿病相关 CKD。在美国、日本、欧盟和其他一些市场，非奈利酮也获批用于治疗左心室射血分数（LVEF）≥40% 的心力衰竭。本次新适应症获受理是基于关键性 III 期 FINE-ONE 研究的积极结果。这项试验的研究对象为慢性肾脏病合并 1 型糖尿病患者，主要研究目标是证明在标准治疗基础上加用非奈利酮是否优于安慰剂，能否在六个月内降低尿白蛋白肌酐比值（UACR）水平。 UACR 是糖尿病相关 CKD 患者肾脏和心血管事件的重要预测指标，UACR 升高提示肾脏损伤加重和心血管风险增加。降低 UACR 与减少肾脏和心血管事件密切相关，在 2 型糖尿病相关 CKD 的关键性 III 期研究（FIDELIO-DKD、FIGARO-DKD）中，非奈利酮降低 UACR 与延缓肾脏疾病进展和肾衰竭以及减少心血管事件密切相关。 FINE-ONE 研究数据表明，在标准治疗的基础上加用非奈利酮，在 6 个月内可显著降低 UACR 这一主要终点指标，即尿白蛋白肌酐比值较基线降低 25%，优于安慰剂组。根据拜耳新闻稿，CKD 影响着 30% 的 1 型糖尿病患者，其中约四分之一会发展为终末期肾病。同时患有 1 型糖尿病和 CKD 的患者面临肾衰竭和心血管疾病 (CVD) 的风险显著增加。非奈利酮有望为这类患者提供一种新的治疗选择。目前，非奈利酮的治疗潜力已在五项关键 III 期临床研究中得到证实，适应症包括左心室射血分数（LVEF）≥40% 的心力衰竭、2 型糖尿病相关 CKD、1 型糖尿病相关 CKD 以及非糖尿病 CKD 患者的心脏和/或肾脏获益。非奈利酮是拜耳处方药业务的第二大增长引擎，上市以来放量很快。2025 年，该药的全球销售额已达 9.38 亿美元，同比增长 87.9%。随着新适应症的不断拓展，该药有望很快跻身重磅炸弹行列。来源：Insight 数据库 Insight 数据库整理了 2026 年全球新药申报上市清单，扫描下方二维码 👇，回复关键词新药报上市即可免费获取（每月初更新一次，目前更新至 4 月）。封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn

临床3期优先审批申请上市

2026-05-25

·今日头条

肾病综合征治疗最新进展：靶向药物、生物制剂与指南更新全解读

肾病综合征（NS）是肾内科最常见的临床综合征之一，以大量蛋白尿（≥3.5g/24h）、低白蛋白血症、高脂血症和水肿四大特征为标志。其背后涉及多种病理类型，包括微小病变（MCD）、局灶节段性肾小球硬化（FSGS）、膜性肾病（MN）及糖尿病肾病等。近年来，随着对疾病机制认识的深化和精准医学的发展，肾病综合征的治疗格局正在经历深刻变革。2025年KDIGO指南更新、美国FDA多项新药获批，以及SGLT2抑制剂、GLP-1受体激动剂等"跨界明星"的加入，共同将NS治疗带入了靶向生物制剂时代。图1：肾病综合征的病理核心——肾小球滤过屏障损伤，导致大量蛋白漏出一、SGLT2抑制剂：从糖尿病到全肾病谱的跨越 2025年1月，美国FDA批准了Ozempic（司美格鲁肽注射剂）用于治疗慢性肾脏病（CKD），这一里程碑事件将SGLT2抑制剂/GLP-1RA类药物正式推入了肾病治疗的核心舞台。以达格列净、恩格列净为代表的SGLT2抑制剂，通过抑制肾小管葡萄糖重吸收，不仅能降低血糖，更被证实具有独立于降糖之外的肾脏保护作用——降低蛋白尿、延缓估算肾小球滤过率（eGFR）下降、降低终末期肾病（ESKD）风险。 2025年KDIGO CKD指南明确建议：对于eGFR≥20 mL/min/1.73m²且伴蛋白尿的CKD患者，无论是否合并糖尿病，均应启动SGLT2抑制剂治疗。这一建议打破了"降糖药"的传统定位，使其成为肾病综合征综合管理的基础用药之一。二、GLP-1受体激动剂：心肾代谢三重获益 GLP-1受体激动剂（司美格鲁肽、利拉鲁肽、替尔泊肽等）在糖尿病合并CKD患者中展现出令人瞩目的心肾保护效果。SELECT研究显示，司美格鲁肽可使合并CVD的肥胖患者心血管事件风险降低20%，同时显著降低尿白蛋白/肌酐比值（UACR）。替尔泊肽（Tirzepatide）作为GIP/GLP-1双受体激动剂，在SURPASS-CVOT研究中进一步证实了其在心肾保护方面的潜力。对于合并肥胖的NS患者，这类药物同时实现减重、降低蛋白尿、改善心血管预后三大目标，开启了代谢-肾脏联合管理的新模式。图2：SGLT2抑制剂与GLP-1RA协同保护肾小球滤过屏障，减少蛋白尿三、非奈利酮：第三代盐皮质激素受体拮抗剂的崛起非奈利酮（Finerenone，Kerendia）是2021年获FDA批准的第二代非甾体选择性盐皮质激素受体拮抗剂（MRA），2025年随着FIDELIO-DKD和FIGARO-DKD研究的亚组分析数据更新，其在糖尿病肾病（DKD）中的保护作用进一步得到确认。与螺内酯、依普利酮相比，非奈利酮对盐皮质激素受体（MR）具有更高选择性，高钾血症风险显著低于传统MRA ，更适合需要长期使用的门诊患者。2025年KDIGO指南推荐非奈利酮用于合并2型糖尿病、eGFR≥25的CKD患者，作为SGLT2i基础上的联合治疗选择。四、生物制剂：从利妥昔单抗到达雷妥尤单抗利妥昔单抗（Rituximab）是第一个广泛应用于NS的靶向生物制剂。2025年KDIGO儿童NS指南将利妥昔单抗列为激素依赖/频繁复发NS的一线替代治疗，显著降低了激素相关不良反应。对于激素抵抗型NS（SRNS），利妥昔单抗联合他克莫司的方案也在多项研究中显示出优于传统免疫抑制的疗效。更值得关注的是达雷妥尤单抗（Daratumumab） ——一种靶向CD38的单克隆抗体，最初用于多发性骨髓瘤，近年在难治性SRNS中展现出突破性疗效。已有病例报告显示，在激素+利妥昔单抗治疗失败的SRNS儿童中，达雷妥尤单抗可实现>50%的蛋白尿下降，部分患者实现完全缓解。2025年，多项关于达雷妥尤单抗在NS中适应症扩展的临床试验正在推进中。图3：2025 KDIGO儿童NS指南推荐的生物制剂阶梯治疗方案五、靶向小分子药物： sparsentan与内皮素受体拮抗剂 2026年4月，美国FDA批准 sparsentan（商品名Filspari）用于治疗局灶节段性肾小球硬化（FSGS），使其成为首个且唯一获批的FSGS治疗药物。Sparsentan是一种双靶点内皮素A受体（ETA）与血管紧张素II受体（AT1）双重拮抗剂，同时在2025年还获批扩展用于IgA肾病治疗。 DUPLEX研究证实， sparsentan治疗FSGS 36周后，可使蛋白尿平均下降约50%，且耐受性良好。这一药物的获批标志着NS治疗从"泛抑制免疫"向"精准靶向发病机制"的范式转变，对于难治性FSGS患者意义重大。六、2025 KDIGO指南核心更新要点（1）激素疗程缩短：指南首次明确建议，激素敏感型NS儿童的激素疗程可缩短至 4~6周（而非传统8~12周），以减少长期使用激素带来的肥胖、骨质疏松、生长发育迟缓等不良反应。这一建议基于多项随机对照试验证据，显示短期激素方案的疗效不劣于长期方案。（2）治疗反应分类细化： 2025版指南引入了"早期激素应答"概念，即在治疗第4周即评估尿蛋白转阴情况，用于预测长期疗效和指导后续治疗决策。这一"时间节点分层"理念帮助临床医生更精准地识别激素抵抗高风险人群。（3）联合用药地位提升：指南明确推荐，对于高危NS患者，应在确诊后即启动 SGLT2i + 免疫抑制剂的联合方案，而非等待传统治疗失败后再升级。这一"早期联合"策略有望改变疾病自然史，延缓向ESKD的进展。七、未来展望：精准医学时代NS管理的愿景展望未来，NS治疗将更加注重"精准"与"联合"：通过尿蛋白组学、基因检测等技术识别患者分子亚型，实现生物标志物驱动的个体化药物选择；SGLT2i、GLP-1RA、非奈利酮的"三联"基础方案联合靶向生物制剂，将成为高危NS患者的标准配置。同时，干细胞疗法（如人脐带间充质干细胞 UCMSC）在难治性NS中的初步数据也令人鼓舞，2期临床试验显示4周内总缓解率可达70%，未来有望成为生物制剂耐药患者的全新选择。 ❤️ 关注我，我是肾内科欧大夫，帮你少走弯路，稳住肾功能。如果你有肾病方面的问题，可以在评论区留言，我会抽时间一一解答。【参考文献】 1. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025;107(5):829-848. 2. KDIGO 2025 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2025;107(5):S1-S78. 3. Travere Therapeutics Announces FDA Approval of FILSPARI (sparsentan) for FSGS. April 2026. 4. DelveInsight. Emerging Nephrotic Syndrome Treatments: A Glimpse Ahead. March 2026. 5. American Kidney Fund. 2025 Advancements in Kidney Disease Research and Treatment. February 2026. #肾病综合征#SGLT2抑制剂#生物制剂#KDIGO指南#非奈利酮#利妥昔单抗#靶向治疗

2026-05-25

·药术

百诚医药或易主

百诚医药5月24日晚间公告，公司于近日收到公司控股股东、实际控制人邵春能、楼金芳的通知，控股股东、实际控制人邵春能、楼金芳及其一致行动人正在筹划涉及公司控制权变更的重大事项，该事宜可能导致公司控制权发生变更。目前，各方主体正在就具体方案、协议等相关事项进行论证和磋商。鉴于上述事项尚存在重大不确定性，为保证公平信息披露，维护投资者利益，避免公司股价异常波动，根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第6号——停复牌》等的有关规定，经公司向深圳证券交易所申请，公司股票将于2026年5月25日（星期一）开市起停牌，预计停牌时间不超过2个交易日。停牌期间，公司将根据上述事项进展情况，严格按照法律法规的规定和要求履行信息披露义务。待上述事项确定后，公司将及时发布相关公告并申请公司股票复牌。百诚医药（301096）成立于2011年6月，是一家以技术开发为核心的，集创新性、全价值链、平台化、共融型属性于一体的综合性医药研发上市公司，聚焦于药品全生命周期（883436）管理，致力于打造医药生态集群，搭建全领域互通桥梁，与合作伙伴实现共融共享高质量发展。业务涵盖靶点设计、靶点验证、化合物制备、成药性评价、有效性评价、药学研究、临床试验、专利设计、全球化注册申报、CDMO/CMO等药物研发及产业化服务全链条。目前，公司累计拥有授权专利34项、专利申请182项、软件著作权34项；已获得4项1类创新药（886015）IND批件及12项2类新药IND批件。业绩方面，百诚医药（301096）2026年一季报显示，报告期内，公司实现营业收入1.6亿元，同比增长24.65%；净利润为1281.25万元，实现扭亏为盈。综合自：公司公告、公司官网，同花顺（总第0223期）国内外分段生产！强生best-in-class重症肌无力Fc单抗中国获批抗失眠1类新药，扬子江药业在国内获批上市！心衰新药「非奈利酮」获批！降低18%心衰风险

100 项与非奈利酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10633	非奈利酮	-	DB16165

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性心力衰竭	日本	Bayer Yakuhin Ltd.	2025-12-22
心脏衰竭	美国	Bayer AG	2025-07-14
2型糖尿病	加拿大	Bayer, Inc.	2022-10-14
慢性肾病	韩国	Bayer AG	2022-05-10
2型糖尿病肾脏病	美国	Bayer HealthCare Pharmaceuticals, Inc.	2021-07-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床3期	加拿大	Bayer AG	2025-12-01
左心室收缩功能障碍	临床3期	美国	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	阿根廷	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	奥地利	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	比利时	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	巴西	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	保加利亚	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	加拿大	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	捷克	Bayer AG	2025-11-19
左心室收缩功能障碍	临床3期	芬兰	Bayer AG	2025-11-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06381323 (Pubmed \| Hypertension)	临床4期	醛固酮增多症	57	Finerenone 20-40 mg/d	鑰糧繭鏇糧鏇願積膚醖(簾鑰鬱餘積遞蓋衊觸鏇) = 遞齋顧觸醖鏇選憲簾鬱遞鏇鹹憲夢鏇繭糧範窪 (網觸選艱醖糧鹹衊艱窪 ) 更多	积极	2026-05-01
NCT02545049 \| NCT02540993 (FIDELIO-DKD, Pubmed \| J Diabetes Complications)	临床3期	2型糖尿病	8,370	Finerenone	齋醖築範願餘膚顧範淵(襯構窪積鹹範壓簾鑰襯): HR = 0.82 (95.0% CI, 0.68 ~ 0.99), P-Value = 0.043 更多	积极	2026-04-01
				Placebo
NCT05047263 (FIND-CKD, Company_Website) 人工标引	临床3期	非糖尿病慢性肾脏病	-	KERENDIA	齋鹹顧壓艱鬱鬱艱鏇鑰(顧觸膚襯齋積遞觸衊積) = The results demonstrated a statistically significant improvement. 壓獵齋鬱觸糧鏇鏇製獵 (艱膚醖糧繭獵窪觸鹹鬱 ) 达到	积极	2026-03-16
				Placebo
NCT04435626 (FINEARTS-HF, Pubmed \| Eur J Heart Fail)	临床2/3期	心脏衰竭	5,006	Finerenone	選製衊鬱膚積觸醖醖構(衊獵範觸艱衊鑰憲壓襯) = 顧膚願顧觸齋鹹構糧夢夢鹹膚窪醖獵遞艱鬱顧 (選餘顧膚網壓鹹鑰遞顧, 0.9 ~ 3.5) 更多	积极	2026-03-12
NCT05901831 (FINE-ONE, Pubmed \| N Engl J Med)	临床3期	1型糖尿病 \| 慢性肾病	242	Finerenone	淵鏇壓窪廠蓋繭齋艱繭(醖膚顧壓獵選糧餘蓋壓): GM ratio = 0.75 (95.0% CI, 0.65 ~ 0.87), P-Value = <0.001 更多	积极	2026-03-05
				Placebo
NCT02545049 \| NCT02540993 (FIDELIO-DKD, Pubmed \| Clin J Am Soc Nephrol)	临床3期	2型糖尿病 \| 慢性肾病	-	Finerenone	顧觸夢顧鹹顧艱醖繭繭(窪齋鹽襯齋糧鑰廠構鬱) = 網選鬱廠顧餘製餘積鬱鬱鏇獵鬱構繭齋膚夢醖 (積齋廠蓋簾衊鹹壓壓餘 ) 更多	积极	2026-03-01
				Placebo	顧觸夢顧鹹顧艱醖繭繭(窪齋鹽襯齋糧鑰廠構鬱) = 築製齋蓋鬱願艱鹹淵廠鬱鏇獵鬱構繭齋膚夢醖 (積齋廠蓋簾衊鹹壓壓餘 ) 更多
NCT04435626 (FINEARTS-HF, Pubmed \| Eur Heart J Cardiovasc Pharmacother)	临床3期	射血分数保留型心力衰竭	6,001	Finerenone	鹽鹹範齋衊構衊構醖築(範鬱艱網艱蓋製廠遞糧): HR = 0.94 (95.0% CI, 0.83 ~ 1.06) 更多	积极	2026-02-16
				Placebo
NCT04435626 (FINEARTS-HF, Pubmed \| Circ Heart Fail)	临床2期	心脏衰竭 total bilirubin \| alkaline phosphatase \| alanine aminotransferase ... 更多	6,001	Finerenone	鹹網醖憲構膚願鑰構壓(艱範窪襯醖鏇窪獵鹹窪) = 簾鏇網壓範齋鏇網餘簾鏇願醖積繭網鹽顧選膚 (蓋壓糧製獵簾網廠鏇壓 )	积极	2026-02-01
NCT04435626 (FINEARTS-HF, Pubmed \| JACC Heart Fail)	临床3期	心脏衰竭	5,873	Finerenone	範膚憲夢壓繭選網淵積(鑰廠顧壓製淵鬱餘艱糧): RR = 0.77 (95.0% CI, 0.63 ~ 0.94) 更多	积极	2026-02-01
				Placebo
NCT05901831 (FINE-ONE, Company_Website \| ASN2025) 人工标引	临床3期	1型糖尿病 \| 慢性肾病	242	Finerenone + SOC	鑰鬱願夢鑰構選鏇膚廠(範鹽齋觸憲夢鬱憲鹽鑰) = 製積獵艱積鹽築壓壓鹹願築鏇壓鏇膚膚積製鏇 (範獵夢膚糧選鏇蓋繭構 ) 达到更多	积极	2025-11-06
				Placebo + SOC	壓鹽願選艱醖齋襯醖簾(觸衊觸願鏇鏇膚壓願遞) = 艱顧選積願繭製獵積醖鑰範鏇餘襯願鏇鹽淵淵 (遞鬱窪餘憲遞觸鑰繭糧 ) 更多